tiprankstipranks
Nuvation Bio (NUVB)
NYSE:NUVB
US Market
Holding NUVB?
Track your performance easily

Nuvation Bio (NUVB) Ownership - Who Owns Nuvation Bio?

199 Followers

Nuvation Bio (NUVB) Ownership Overview

27.30%10.63%27.69%7.25%27.14%
27.30% Insiders
27.69% Other Institutional Investors
7.25% ETFs
27.14% Public Companies and
Individual Investors
The ownership structure of Nuvation Bio (NUVB) stock is a mix of institutional, retail, and individual investors. Approximately 45.57% of the company’s stock is owned by Institutional Investors, 27.30% is owned by Insiders, and 27.14% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Nov 13, 2024
Junyuan Jerry Wang
Ceo, Anheart Therapeutics Ltd,director
xxxxxxxxxxxxx
$162883
Oct 10, 2024
xxxxxxxxxxxxx
$220000
Jun 26, 2024
Xiangmin Cui
Director
xxxxxxxxxxxxx
$825348
Jun 25, 2024
Xiangmin Cui
Director
xxxxxxxxxxxxx
$1492385

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
58,281,054Insider17.32%150,947,930
25,954,439Insider7.71%67,221,997
14,132,421Institution4.20%36,602,970
13,072,340Institution3.88%33,857,361
10,331,549Institution3.07%26,758,712
10,072,582Institution2.99%26,087,987
8,457,071Institution2.51%21,903,814
6,112,686Insider1.82%15,831,857
3,811,513Institution1.13%9,871,819
3,123,214Institution0.93%8,089,124

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
14,132,421Institution4.20%36,602,970
8,457,071Institution2.51%21,903,814
3,123,214Institution0.93%8,089,124
2,051,818Institution0.61%5,314,209
1,587,440Institution0.47%4,111,470
1,235,228Institution0.37%3,199,241
870,755Institution0.26%2,255,255
761,442Institution0.23%1,972,135
644,704Institution0.19%1,669,783
504,523Institution0.15%1,306,715

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
6,128,150Institution1.82%14,033,464
4,983,944Institution1.48%12,908,415
2,446,258Institution0.73%5,601,931
1,753,809Institution0.52%4,542,365
1,602,749Institution0.48%4,151,120
817,641Institution0.24%2,093,161
832,841Institution0.25%1,907,206
483,620Institution0.14%1,271,921
495,739Institution0.15%1,135,242
417,120Institution0.12%1,080,341

FAQ

Who Owns Nuvation Bio (NUVB)?
According to the latest TipRanks data, approximately 27.69% of the company's stock is held by institutional investors, 27.30% is held by insiders, and 27.14% is held by retail investors.
    What percentage of Nuvation Bio (NUVB) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 27.69% of Nuvation Bio (NUVB) stock is held by institutional investors.
      What percentage of Nuvation Bio (NUVB) stock is held by retail investors?
      According to the latest TipRanks data, approximately 27.14% of Nuvation Bio (NUVB) stock is held by retail investors.
        Who owns the most shares of Nuvation Bio (NUVB)?
        David Hung owns the most shares of Nuvation Bio (NUVB).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis